Xlife Sciences AG Moves to Main SIX Swiss Exchange Segment to Enhance Market Position

Xlife Sciences AG (SIX: XLS) announced that its Board of Directors has resolved to move from the SIX Sparks segment to the main segment of the SIX Swiss Exchange. This step underscores the company’s strategic development and offers significant advantages for investors: increased visibility, improved liquidity, and stronger recognition in the capital markets. Following a preliminary legal review, Xlife Sciences meets all requirements and will promptly submit the corresponding application to SIX. The segment change is planned for the first quarter of 2026.

In addition, Xlife Sciences is investing in market-making and research activities to further enhance the visibility and tradability of its shares. Oliver R. Baumann, CEO of Xlife Sciences AG, stated that transitioning to the main segment of SIX is the next logical step for the company, as it increases visibility, improves the liquidity of shares, and provides additional access to institutional investors. Baumann added that the company is intensifying efforts in market-making and research coverage to further enhance attractiveness for existing and new shareholders.

This move matters because it signals Xlife Sciences' maturation and readiness for broader market engagement, potentially attracting more institutional investment and stabilizing share performance. The implications include heightened scrutiny from analysts and investors, which could drive more rigorous financial reporting and strategic transparency. For the life sciences sector, it highlights how incubator models like Xlife Sciences, which focuses on value development and commercialization of research projects, can achieve milestones that warrant main market listings. The company aims to bridge research and development to healthcare markets, taking projects in technological platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health to the next stage of development.

The transition aligns with Xlife Sciences' financial calendar, including the Annual Report 2025 on April 28, 2026, the Annual Shareholders Meeting 2026 on June 26, 2026, and the Half-Year Report 2026 on September 24, 2026. For more information, visit https://www.xlifesciences.ch. The announcement contains forward-looking statements that are not guarantees of future performance and involve risks and uncertainties, with actual results potentially differing materially. Xlife Sciences undertakes no obligation to publicly update or revise any forward-looking statements. The original release can be viewed on www.newmediawire.com.